GlobalMed Telemedicine

globalmed.com

Founded in early 2002 in Scottsdale, Arizona, GlobalMed is a real-time healthcare delivery system company that deploys state-of-the-art hardware, software, and service solutions that enable leading healthcare professionals to be more effective in providing patient care and more efficient in managing patient information. As the worldwide leader in telemedicine and only vertically-integrated provider, GlobalMed technologies enable more than 3 million telehealth consults annually and are deployed in more than 55 countries around the world. Our evidence-based solutions include telemedicine stations, examination cameras, connected medical devices, video conferencing tools, and software that allow for the dynamic collaboration of healthcare professionals at remote locations across the globe. Partnering with leading medical groups, healthcare enterprises, and government agencies has led to our unparalleled expertise in designing sustainable, integrated connected health programs that deliver best-in-class patient care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

news image

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More

Cell and Gene Therapy

ROCKET PHARMACEUTICALS TO ACQUIRE RENOVACOR, EXTENDING LEADERSHIP IN AAV-BASED CARDIAC GENE THERAPY

Rocket Pharmaceuticals, Inc. | September 21, 2022

news image

Rocket Pharmaceuticals, Inc. a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, and Renovacor, Inc. a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced a definitive agreement under which Rocket will acquire Re...

Read More

Medical, Industry Outlook

BIOIVT ACQUIRES PRECISIONMED, A LEADING GLOBAL PROVIDER OF BIOSPECIMENS FOR NEUROLOGY AND ONCOLOGY RESEARCH

PRNewswire | July 19, 2023

news image

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, announced today that it has acquired PrecisionMed, LLC, a leading supplier of high-quality human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics. Based in Carlsbad, CA, PrecisionMed has been collecting biospecimens for neurology and oncology research for more than 27 years, and it has the largest private, global repository of...

Read More

QUENCH BIO EMERGES WITH $50M TO TREAT SEVERE INFLAMMATORY DISEASES

Labiotech.eu | January 27, 2020

news image

Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...

Read More
news image

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More
news image

Cell and Gene Therapy

ROCKET PHARMACEUTICALS TO ACQUIRE RENOVACOR, EXTENDING LEADERSHIP IN AAV-BASED CARDIAC GENE THERAPY

Rocket Pharmaceuticals, Inc. | September 21, 2022

Rocket Pharmaceuticals, Inc. a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, and Renovacor, Inc. a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced a definitive agreement under which Rocket will acquire Re...

Read More
news image

Medical, Industry Outlook

BIOIVT ACQUIRES PRECISIONMED, A LEADING GLOBAL PROVIDER OF BIOSPECIMENS FOR NEUROLOGY AND ONCOLOGY RESEARCH

PRNewswire | July 19, 2023

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, announced today that it has acquired PrecisionMed, LLC, a leading supplier of high-quality human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics. Based in Carlsbad, CA, PrecisionMed has been collecting biospecimens for neurology and oncology research for more than 27 years, and it has the largest private, global repository of...

Read More
news image

QUENCH BIO EMERGES WITH $50M TO TREAT SEVERE INFLAMMATORY DISEASES

Labiotech.eu | January 27, 2020

Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us